董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kathleen Walsh | 女 | Director | 70 | 46.57万美元 | 6.48 | 2026-02-27 |
| Carole Ho | 女 | Director | 53 | 47.07万美元 | 未持股 | 2026-02-27 |
| Chirfi Guindo | 男 | Director | 60 | 45.57万美元 | 1.51 | 2026-02-27 |
| Christi Shaw | 女 | Director | 59 | 46.32万美元 | 5.13 | 2026-02-27 |
| John Evans | 男 | Chief Executive Officer and Director | 48 | 581.85万美元 | 203.32 | 2026-02-27 |
| Mark Fishman | 男 | Director | 74 | 49.52万美元 | 33.42 | 2026-02-27 |
| ジョンマラガノア | 男 | Director | 64 | 46.57万美元 | 6.32 | 2026-02-27 |
| Graham Cooper | 男 | Director | 56 | 46.82万美元 | 7.35 | 2026-02-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Evans | 男 | Chief Executive Officer and Director | 48 | 581.85万美元 | 203.32 | 2026-02-27 |
| Giuseppe Ciaramella | 男 | President | 57 | 316.03万美元 | 82.52 | 2026-02-27 |
| Sravan K. Emany | 男 | Chief Financial Officer | 47 | 129.65万美元 | 6.04 | 2026-02-27 |
| Christine Bellon | 女 | Chief Legal Officer and Secretary | 60 | 196.72万美元 | 22.70 | 2026-02-27 |
| Amy Simon | 女 | Chief Medical Officer | 61 | 280.20万美元 | 19.48 | 2026-02-27 |
董事简历
中英对照 | 中文 | 英文- Kathleen Walsh
-
Kathleen Walsh，她担任董事会成员（2016年2月以来）。2010年以来，她一直担任Boston Medical Center的总裁兼首席执行官。任职Boston Medical Center之前，她曾担任Brigham and Women’s Hospital的执行副总裁兼首席运营官5年。2002年至2004年，她曾担任Novartis Institutes for Biomedical Research的首席运营官。1988年至2002年，她曾担任Massachusetts General Hospital的多种职务，并不断被提拔，最终担任高级医疗服务副总裁。
Kathleen Walsh has served as a member of the Board of Directors since February 2016. Since 2010 Ms. Walsh has been President and Chief Executive Officer of Boston Medical Center. Prior to her appointment at Boston Medical Center, Ms. Walsh served as Executive Vice President and Chief Operating Officer of Brigham and Women's Hospital for five years. From 2002 to 2004 she served as the Chief Operating Officer for Novartis Institutes for Biomedical Research and from 1988 to 2002 Ms. Walsh served in progressively more responsible roles ultimately serving as Senior Vice President of Medical Services at Massachusetts General Hospital. - Kathleen Walsh，她担任董事会成员（2016年2月以来）。2010年以来，她一直担任Boston Medical Center的总裁兼首席执行官。任职Boston Medical Center之前，她曾担任Brigham and Women’s Hospital的执行副总裁兼首席运营官5年。2002年至2004年，她曾担任Novartis Institutes for Biomedical Research的首席运营官。1988年至2002年，她曾担任Massachusetts General Hospital的多种职务，并不断被提拔，最终担任高级医疗服务副总裁。
- Kathleen Walsh has served as a member of the Board of Directors since February 2016. Since 2010 Ms. Walsh has been President and Chief Executive Officer of Boston Medical Center. Prior to her appointment at Boston Medical Center, Ms. Walsh served as Executive Vice President and Chief Operating Officer of Brigham and Women's Hospital for five years. From 2002 to 2004 she served as the Chief Operating Officer for Novartis Institutes for Biomedical Research and from 1988 to 2002 Ms. Walsh served in progressively more responsible roles ultimately serving as Senior Vice President of Medical Services at Massachusetts General Hospital.
- Carole Ho
-
Carole Ho自2018年11月以来一直担任我们的董事会成员。Ho博士自2015年6月起担任Denali Therapeutics的首席医疗官兼开发主管。在加入Denali之前，Ho博士在2007年至2015年期间在Genentech担任各种职责递增的职务，最近担任Vice President，非肿瘤学早期临床开发。从2006年11月到2007年10月，何博士担任强生公司的副医疗主任。从2002年6月到2006年11月，她曾担任斯坦福大学（Stanford University）的神经病学和神经科学部门的讲师。Ho博士在康奈尔大学（Cornell University）获得医学博士学位，在哈佛学院（Harvard College）获得生化科学学士学位。
Carole Ho,has served as the Chief Medical Officer and Head of Development of Denali Therapeutics, a biotechnology company, since June 2015. Prior to joining Denali, Dr. Ho held various roles of increasing responsibility at Genentech, a biotechnology company, between 2007 and 2015 most recently as Vice President, Non-Oncology Early Clinical Development. From November 2006 to October 2007, Dr. Ho served as Associate Medical Director at Johnson & Johnson, a pharmaceutical company. From June 2002 to November 2006, she was an instructor in the Department of Neurology and Neurological Sciences at Stanford University. Dr. Ho has also served as a member of the board of directors of NGM Biopharmaceuticals, Inc., a biopharmaceutical company, since June 2020. Dr. Ho received her M.D. from Cornell University and her B.S. in Biochemical Sciences from Harvard College. - Carole Ho自2018年11月以来一直担任我们的董事会成员。Ho博士自2015年6月起担任Denali Therapeutics的首席医疗官兼开发主管。在加入Denali之前，Ho博士在2007年至2015年期间在Genentech担任各种职责递增的职务，最近担任Vice President，非肿瘤学早期临床开发。从2006年11月到2007年10月，何博士担任强生公司的副医疗主任。从2002年6月到2006年11月，她曾担任斯坦福大学（Stanford University）的神经病学和神经科学部门的讲师。Ho博士在康奈尔大学（Cornell University）获得医学博士学位，在哈佛学院（Harvard College）获得生化科学学士学位。
- Carole Ho,has served as the Chief Medical Officer and Head of Development of Denali Therapeutics, a biotechnology company, since June 2015. Prior to joining Denali, Dr. Ho held various roles of increasing responsibility at Genentech, a biotechnology company, between 2007 and 2015 most recently as Vice President, Non-Oncology Early Clinical Development. From November 2006 to October 2007, Dr. Ho served as Associate Medical Director at Johnson & Johnson, a pharmaceutical company. From June 2002 to November 2006, she was an instructor in the Department of Neurology and Neurological Sciences at Stanford University. Dr. Ho has also served as a member of the board of directors of NGM Biopharmaceuticals, Inc., a biopharmaceutical company, since June 2020. Dr. Ho received her M.D. from Cornell University and her B.S. in Biochemical Sciences from Harvard College.
- Chirfi Guindo
-
Chirfi Guindo自2019年2月起担任Biogen Inc.的执行副总裁，负责全球产品战略和商业化。此前，他曾担任Biogen Inc.的执行副总裁兼全球营销、市场准入和客户创新主管（2017年11月至2019年2月）。加入Biogen之前，他在全球制药行业工作了27年，并在Merck制药公司（加拿大、美国、法国、非洲和荷兰）担任多个领导职务。他曾在多个学科工作，包括财务、销售和市场营销、综合管理和全球战略/产品开发，涉及专业、急症和医院护理。2014年10月至2017年11月，他担任Merck Canada的副总裁兼董事总经理、总裁兼董事总经理。从2011年1月到2014年10月，他担任Merck公司全球艾滋病毒特许经营副总裁兼总经理。法国巴黎中央学校，工程专业；纽约大学斯特恩商学院，金融/经济学工商管理硕士。
Chirfi Guindo,Senior Vice President, Chief Marketing Officer, Human Health (since July 2022); Prior to that, Executive Vice President, Head of Global Product Strategy and Commercialization, Biogen Inc. (July 2018-July 2022). - Chirfi Guindo自2019年2月起担任Biogen Inc.的执行副总裁，负责全球产品战略和商业化。此前，他曾担任Biogen Inc.的执行副总裁兼全球营销、市场准入和客户创新主管（2017年11月至2019年2月）。加入Biogen之前，他在全球制药行业工作了27年，并在Merck制药公司（加拿大、美国、法国、非洲和荷兰）担任多个领导职务。他曾在多个学科工作，包括财务、销售和市场营销、综合管理和全球战略/产品开发，涉及专业、急症和医院护理。2014年10月至2017年11月，他担任Merck Canada的副总裁兼董事总经理、总裁兼董事总经理。从2011年1月到2014年10月，他担任Merck公司全球艾滋病毒特许经营副总裁兼总经理。法国巴黎中央学校，工程专业；纽约大学斯特恩商学院，金融/经济学工商管理硕士。
- Chirfi Guindo,Senior Vice President, Chief Marketing Officer, Human Health (since July 2022); Prior to that, Executive Vice President, Head of Global Product Strategy and Commercialization, Biogen Inc. (July 2018-July 2022).
- Christi Shaw
-
Christi Shaw是Eli Lilly公司的高级副总裁，Eli Lilly公司是一家全球医疗保健公司，也是礼来生物医药公司的总裁，礼来公司是Eli Lilly公司的业务部门，其中包括自2017年4月以来一直担任的神经科学和免疫学。2014年至2016年，Shaw女士担任全球医疗保健公司Novartis Pharmaceutical Corporation的美国区域负责人和总裁，并于2010年至2014年担任诺华公司的北美地区负责人。2010年之前，Shaw女士在强生公司担任多个领导职务。Shaw女士还担任生物技术创新组织的执行董事会成员，并且是More Moments More Memories Foundation的联合创始人。Shaw女士拥有爱荷华州立大学市场营销学士学位和威斯康星大学工商管理硕士学位。
Christi Shaw has served as a member of Kyverna Therapeutics, Inc.'s Board since September 2024 and as Executive Chairperson of Kyverna Therapeutics, Inc.'s Board since January 12, 2026. Ms. Shaw is a seasoned healthcare executive with over 30 years of experience in the biopharmaceutical industry. Most recently, she served as Chief Executive Officer of Kite Pharma, Inc., a Gilead company specializing in the development of cancer immunotherapies, from August 2019 to March 2023. Ms. Shaw has served on the board of directors of Beam Therapeutics Inc. (Nasdaq: BEAM) since December 2023 and on the board of directors for ReAlta Life Sciences, Inc. from January 2024 until September 2025. Ms. Shaw also served as a director of Avantor, Inc. (NYSE: AVTR) from November 2018 through May 2024. From April 2017 to August 2019, she served as Senior Vice President of Eli Lilly & Co. (NYSE: LLY), a global healthcare company, and President of Lilly Bio Medicines, the business within Eli Lilly Company that comprised its neuroscience and immunology divisions. From 2014 to 2016, Ms. Shaw served as U.S. country head and President of Novartis Pharmaceutical Corporation, a global healthcare company, and from 2010 to 2014, as North American region head of Novartis Oncology. Prior to 2010, Ms. Shaw held several leadership positions at Johnson & Johnson, Inc. (NYSE: JNJ). Previously, she served as an executive committee member of the Biotechnology Innovation Organization. Ms. Shaw is also an advisor for Family Reach's Clinical Trial Access Program, which she co founded with her sister (More Moments More Memories) to assist people with cancer access clinical trials. Ms. Shaw holds a B.B.A. in Marketing from Iowa State University and an M.B.A. from the University of Wisconsin. - Christi Shaw是Eli Lilly公司的高级副总裁，Eli Lilly公司是一家全球医疗保健公司，也是礼来生物医药公司的总裁，礼来公司是Eli Lilly公司的业务部门，其中包括自2017年4月以来一直担任的神经科学和免疫学。2014年至2016年，Shaw女士担任全球医疗保健公司Novartis Pharmaceutical Corporation的美国区域负责人和总裁，并于2010年至2014年担任诺华公司的北美地区负责人。2010年之前，Shaw女士在强生公司担任多个领导职务。Shaw女士还担任生物技术创新组织的执行董事会成员，并且是More Moments More Memories Foundation的联合创始人。Shaw女士拥有爱荷华州立大学市场营销学士学位和威斯康星大学工商管理硕士学位。
- Christi Shaw has served as a member of Kyverna Therapeutics, Inc.'s Board since September 2024 and as Executive Chairperson of Kyverna Therapeutics, Inc.'s Board since January 12, 2026. Ms. Shaw is a seasoned healthcare executive with over 30 years of experience in the biopharmaceutical industry. Most recently, she served as Chief Executive Officer of Kite Pharma, Inc., a Gilead company specializing in the development of cancer immunotherapies, from August 2019 to March 2023. Ms. Shaw has served on the board of directors of Beam Therapeutics Inc. (Nasdaq: BEAM) since December 2023 and on the board of directors for ReAlta Life Sciences, Inc. from January 2024 until September 2025. Ms. Shaw also served as a director of Avantor, Inc. (NYSE: AVTR) from November 2018 through May 2024. From April 2017 to August 2019, she served as Senior Vice President of Eli Lilly & Co. (NYSE: LLY), a global healthcare company, and President of Lilly Bio Medicines, the business within Eli Lilly Company that comprised its neuroscience and immunology divisions. From 2014 to 2016, Ms. Shaw served as U.S. country head and President of Novartis Pharmaceutical Corporation, a global healthcare company, and from 2010 to 2014, as North American region head of Novartis Oncology. Prior to 2010, Ms. Shaw held several leadership positions at Johnson & Johnson, Inc. (NYSE: JNJ). Previously, she served as an executive committee member of the Biotechnology Innovation Organization. Ms. Shaw is also an advisor for Family Reach's Clinical Trial Access Program, which she co founded with her sister (More Moments More Memories) to assist people with cancer access clinical trials. Ms. Shaw holds a B.B.A. in Marketing from Iowa State University and an M.B.A. from the University of Wisconsin.
- John Evans
-
John Evans自2018年8月起担任Verve Therapeutics, Inc.的董事会成员。Evans先生自2018年1月起担任生物技术公司Beam Therapeutics Inc.的首席执行官，并于2017年4月至2018年1月担任临时首席执行官。Evans先生与ARCH venture Partners担任风险合伙人，埃文斯先生曾于2009年9月至2017年3月受雇于生物制药公司Agios Pharmaceuticals，Inc.，最近担任公司发展和投资组合领导高级副总裁。在Agios，Evans先生还担任IDH投资组合执行官。在加入Agios之前，Evans先生曾就职于生物制药公司Infinity Pharmaceuticals，Inc.，麦肯锡公司的制药业务和生物制药公司AstraZeneca plc的全球生物制剂研发部门Medimune，LLC.伊万斯先生也在梁治疗公司董事会任职。伊万斯先生持有耶鲁大学的B.A，宾夕法尼亚大学的生物技术硕士学位和宾夕法尼亚大学沃顿商学院的医疗管理硕士学位。
John Evans,has significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Since September 2022, Mr. Evans has also served on the board of directors of Orbital Therapeutics, Inc., a biotechnology company focused on mRNA therapeutics. Mr. Evans previously served as a Venture Partner with ARCH Venture Partners from April 2017 to March 2021, and as a member of the board of directors of Verve Therapeutics from August 2018 to August 2022 and of Prime Medicines Inc. from September 2019 to September 2022. Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, from September 2009 until April 2017, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company's pharmaceuticals practice and MedImmune. Mr. Evans holds an MBA in Healthcare Management from Wharton, a M.S. in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University. - John Evans自2018年8月起担任Verve Therapeutics, Inc.的董事会成员。Evans先生自2018年1月起担任生物技术公司Beam Therapeutics Inc.的首席执行官，并于2017年4月至2018年1月担任临时首席执行官。Evans先生与ARCH venture Partners担任风险合伙人，埃文斯先生曾于2009年9月至2017年3月受雇于生物制药公司Agios Pharmaceuticals，Inc.，最近担任公司发展和投资组合领导高级副总裁。在Agios，Evans先生还担任IDH投资组合执行官。在加入Agios之前，Evans先生曾就职于生物制药公司Infinity Pharmaceuticals，Inc.，麦肯锡公司的制药业务和生物制药公司AstraZeneca plc的全球生物制剂研发部门Medimune，LLC.伊万斯先生也在梁治疗公司董事会任职。伊万斯先生持有耶鲁大学的B.A，宾夕法尼亚大学的生物技术硕士学位和宾夕法尼亚大学沃顿商学院的医疗管理硕士学位。
- John Evans,has significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Since September 2022, Mr. Evans has also served on the board of directors of Orbital Therapeutics, Inc., a biotechnology company focused on mRNA therapeutics. Mr. Evans previously served as a Venture Partner with ARCH Venture Partners from April 2017 to March 2021, and as a member of the board of directors of Verve Therapeutics from August 2018 to August 2022 and of Prime Medicines Inc. from September 2019 to September 2022. Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, from September 2009 until April 2017, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company's pharmaceuticals practice and MedImmune. Mr. Evans holds an MBA in Healthcare Management from Wharton, a M.S. in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.
- Mark Fishman
-
Mark Fishman自2018年5月以来一直担任我们的董事会成员。Fishman博士是Harvard Department of Stem Cell and Regenerative Biology的教授和Massachusetts General Hospital的Pathways Clinical Service的首席。2019年2月，他成为Aditum Bio Fund的联合创始合伙人，并担任其科学和医疗咨询委员会主席。Fishman从2002年到2016年担任Novartis Institutes for Biomedical Research NIBR创始总裁，Novartis，AG执行委员会成员，以及在Novartis International Pharmaceutical Ltd的董事会任职，并担任Novartis Research Foundation基因组学研究所的董事会主席。任职NIBR公司之前，他曾担任the Cardiovascular Research Center的创始董事，以及Massachusetts General Hospital的心脏病首席。Fishman博士还自2016年起担任私人持有的Semma Therapeutics的董事会主席。他还担任其他几家私人持有的生物技术公司的顾问和科学顾问委员会成员。Fishman博士毕业于耶鲁学院（Yale College）和哈佛医学院（Harvard Medical School），并在马萨诸塞州总医院（Massachusetts General Hospital）接受医学和心脏病学培训。
Mark Fishman,is a Professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Clinical Service at Massachusetts General Hospital. In February 2019, he became a Co-Founding Partner of Aditum Bio Fund and Chairman of its Scientific and Medical Advisory Board. From 2002 through 2016, Dr. Fishman was the founding President of the Novartis Institutes for BioMedical Research ("NIBR"), a member of the Executive Committee of Novartis, AG, and served on the Board of Directors of Novartis International Pharmaceutical LTD and Chaired the Board of Directors of the Genomics Institute of the Novartis Research Foundation. Prior to his time at NIBR, he was the Founding Director of the Cardiovascular Research Center and Chief of Cardiology at Massachusetts General Hospital. He also serves as a consultant to and Scientific Advisory Board member of several other privately held biotechnology companies. Dr. Fishman graduated from Yale College and Harvard Medical School and trained in medicine and cardiology at Massachusetts General Hospital. - Mark Fishman自2018年5月以来一直担任我们的董事会成员。Fishman博士是Harvard Department of Stem Cell and Regenerative Biology的教授和Massachusetts General Hospital的Pathways Clinical Service的首席。2019年2月，他成为Aditum Bio Fund的联合创始合伙人，并担任其科学和医疗咨询委员会主席。Fishman从2002年到2016年担任Novartis Institutes for Biomedical Research NIBR创始总裁，Novartis，AG执行委员会成员，以及在Novartis International Pharmaceutical Ltd的董事会任职，并担任Novartis Research Foundation基因组学研究所的董事会主席。任职NIBR公司之前，他曾担任the Cardiovascular Research Center的创始董事，以及Massachusetts General Hospital的心脏病首席。Fishman博士还自2016年起担任私人持有的Semma Therapeutics的董事会主席。他还担任其他几家私人持有的生物技术公司的顾问和科学顾问委员会成员。Fishman博士毕业于耶鲁学院（Yale College）和哈佛医学院（Harvard Medical School），并在马萨诸塞州总医院（Massachusetts General Hospital）接受医学和心脏病学培训。
- Mark Fishman,is a Professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Clinical Service at Massachusetts General Hospital. In February 2019, he became a Co-Founding Partner of Aditum Bio Fund and Chairman of its Scientific and Medical Advisory Board. From 2002 through 2016, Dr. Fishman was the founding President of the Novartis Institutes for BioMedical Research ("NIBR"), a member of the Executive Committee of Novartis, AG, and served on the Board of Directors of Novartis International Pharmaceutical LTD and Chaired the Board of Directors of the Genomics Institute of the Novartis Research Foundation. Prior to his time at NIBR, he was the Founding Director of the Cardiovascular Research Center and Chief of Cardiology at Massachusetts General Hospital. He also serves as a consultant to and Scientific Advisory Board member of several other privately held biotechnology companies. Dr. Fishman graduated from Yale College and Harvard Medical School and trained in medicine and cardiology at Massachusetts General Hospital.
- ジョンマラガノア
-
John Maraganore是City Therapeutics，Inc.的联合创始人之一，自2023年9月起担任City Therapeutics，Inc.的执行主席和City Therapeutics，Inc.的董事会成员。Maraganore博士自2022年1月起担任战略咨询公司JMM Innovations，LLC的负责人，并自2024年9月起担任私营生物技术公司Corsera Health，Inc.的联合首席执行官。他目前还担任ARCH Venture Partners的风险合伙人、Atlas Venture的风险顾问、Blackstone Life Sciences的高级顾问、杰富瑞金融服务的高级顾问以及RTW Investments，LP的执行合伙人，RTW Investments，LP均为一家投资和风险投资公司。此前，Maraganore博士曾于2002年12月至2021年12月担任Alnylam的创始首席执行官和董事会成员，并于2002年12月至2007年12月担任Alnylam的总裁。Maraganore博士目前在Kymera Therapeutics, Inc.（纳斯达克：KYMR）、Beam Therapeutics Inc.（纳斯达克：BEAM）（“Beam Therapeutics”）、Rapport Therapeutics，Inc.（纳斯达克：RAPP）、Hemab Therapeutics Holdings，Inc.（丨纳斯达克纳斯达克：COAG）和Takeda Pharmaceutical Company Limited（纽约证券交易所代码：TAK）的董事会任职。他此前曾于2010年6月至2023年5月在Agios制药公司（纳斯达克：AGIO）董事会任职，于2022年8月至2024年5月在ProKidney Corp.（纳斯达克：PROK）董事会任职。Maraganore博士分别获得了芝加哥大学的生物科学学士学位和生物化学和分子生物学硕士学位和博士学位。
John Maraganore one of City Therapeutics, Inc.'s co founders, has served as City Therapeutics, Inc.'s Executive Chair and a member of City Therapeutics, Inc.'s board of directors since September 2023. Dr. Maraganore has served as Principal of JMM Innovations, LLC, a strategic consulting firm, since January 2022, and as Co Chief Executive Officer of Corsera Health, Inc., a privately held biotechnology company, since September 2024. He also currently serves as a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Venture, a Senior Advisor at Blackstone Life Sciences, a Senior Advisor at Jefferies Financial Services, and an Executive Partner at RTW Investments, LP, each an investment and venture capital firm. Previously, Dr. Maraganore served as founding Chief Executive Officer and as a member of the board of directors of Alnylam from December 2002 to December 2021, and as President of Alnylam from December 2002 to December 2007. Dr. Maraganore currently serves on the boards of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR), Beam Therapeutics Inc. (Nasdaq: BEAM) ("Beam Therapeutics"), Rapport Therapeutics, Inc. (Nasdaq: RAPP), Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) and Takeda Pharmaceutical Company Limited (NYSE: TAK). He previously served on the boards of directors of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) from June 2010 to May 2023 and ProKidney Corp. (Nasdaq: PROK) from August 2022 to May 2024. Dr. Maraganore received a B.A. in Biological Sciences and M.S. and Ph.D. degrees in Biochemistry and Molecular Biology, each from the University of Chicago. - John Maraganore是City Therapeutics，Inc.的联合创始人之一，自2023年9月起担任City Therapeutics，Inc.的执行主席和City Therapeutics，Inc.的董事会成员。Maraganore博士自2022年1月起担任战略咨询公司JMM Innovations，LLC的负责人，并自2024年9月起担任私营生物技术公司Corsera Health，Inc.的联合首席执行官。他目前还担任ARCH Venture Partners的风险合伙人、Atlas Venture的风险顾问、Blackstone Life Sciences的高级顾问、杰富瑞金融服务的高级顾问以及RTW Investments，LP的执行合伙人，RTW Investments，LP均为一家投资和风险投资公司。此前，Maraganore博士曾于2002年12月至2021年12月担任Alnylam的创始首席执行官和董事会成员，并于2002年12月至2007年12月担任Alnylam的总裁。Maraganore博士目前在Kymera Therapeutics, Inc.（纳斯达克：KYMR）、Beam Therapeutics Inc.（纳斯达克：BEAM）（“Beam Therapeutics”）、Rapport Therapeutics，Inc.（纳斯达克：RAPP）、Hemab Therapeutics Holdings，Inc.（丨纳斯达克纳斯达克：COAG）和Takeda Pharmaceutical Company Limited（纽约证券交易所代码：TAK）的董事会任职。他此前曾于2010年6月至2023年5月在Agios制药公司（纳斯达克：AGIO）董事会任职，于2022年8月至2024年5月在ProKidney Corp.（纳斯达克：PROK）董事会任职。Maraganore博士分别获得了芝加哥大学的生物科学学士学位和生物化学和分子生物学硕士学位和博士学位。
- John Maraganore one of City Therapeutics, Inc.'s co founders, has served as City Therapeutics, Inc.'s Executive Chair and a member of City Therapeutics, Inc.'s board of directors since September 2023. Dr. Maraganore has served as Principal of JMM Innovations, LLC, a strategic consulting firm, since January 2022, and as Co Chief Executive Officer of Corsera Health, Inc., a privately held biotechnology company, since September 2024. He also currently serves as a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Venture, a Senior Advisor at Blackstone Life Sciences, a Senior Advisor at Jefferies Financial Services, and an Executive Partner at RTW Investments, LP, each an investment and venture capital firm. Previously, Dr. Maraganore served as founding Chief Executive Officer and as a member of the board of directors of Alnylam from December 2002 to December 2021, and as President of Alnylam from December 2002 to December 2007. Dr. Maraganore currently serves on the boards of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR), Beam Therapeutics Inc. (Nasdaq: BEAM) ("Beam Therapeutics"), Rapport Therapeutics, Inc. (Nasdaq: RAPP), Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) and Takeda Pharmaceutical Company Limited (NYSE: TAK). He previously served on the boards of directors of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) from June 2010 to May 2023 and ProKidney Corp. (Nasdaq: PROK) from August 2022 to May 2024. Dr. Maraganore received a B.A. in Biological Sciences and M.S. and Ph.D. degrees in Biochemistry and Molecular Biology, each from the University of Chicago.
- Graham Cooper
-
Graham Cooper，自2013年2月起，他曾担任Receptos公司的首席财务官，一家专注治疗免疫系统疾病的公开上市的生物制药公司。2006年5月至2011年3月，他担任Orexigen治疗公司的财务总监，一家专注于肥胖症的治疗生物技术公司。2012年1月至2012年12月，他担任Orexigen 制药公司的首席财务官，一家侧重于癌症治疗的生物制药公司。1999年至2006年，他担任越来越重要的职务，包括医疗保健投资银行的董事长；德意志银行证券—— 一家全球领先的投资银行，在那里他负责生命科学领域的执行和管理各种融资及并购交易。1992年8月至1995年1月，他曾担任德勤会计师事务所的会计师，一家独立注册会计师事务所；曾任会计师。他拥有美国加州大学伯克利分校文学士学位和斯坦福商学院经济学的工商管理硕士学位。
Graham Cooper has served as a member of Board since October 2017. Mr. Cooper served as Chief Financial Officer and Chief Operating Officer of Assembly Biosciences, Inc. from March 2018 until April 2019. Mr. Cooper served as the Chief Financial Officer of Receptos, Inc. from February 2013 to August 2015 and as the Chief Financial Officer and Executive Vice President of Finance & Business Development at Geron Corporation from January 2012 to December 2012. Prior to that, Mr. Cooper served as Chief Financial Officer of Orexigen Therapeutics, Inc. and held several positions at Deutsche Bank Securities, including Director, Health Care Investment Banking. Mr. Cooper also worked as an accountant at Deloitte & Touche LLP, where he earned his CPA. Mr. Cooper has served as a member of the board of directors of Applied Molecular Therapeutics, Inc. since January 2020 Beam Therapeutics, Inc. since October 2019 and Unity Biotechnology, Inc. since August 2017. Mr. Cooper previously served as a member of the board of directors of Celladon Corporation. Mr. Cooper received a B.A. degree in economics from the University of California at Berkeley and an M.B.A. degree from the Stanford Graduate School of Business. - Graham Cooper，自2013年2月起，他曾担任Receptos公司的首席财务官，一家专注治疗免疫系统疾病的公开上市的生物制药公司。2006年5月至2011年3月，他担任Orexigen治疗公司的财务总监，一家专注于肥胖症的治疗生物技术公司。2012年1月至2012年12月，他担任Orexigen 制药公司的首席财务官，一家侧重于癌症治疗的生物制药公司。1999年至2006年，他担任越来越重要的职务，包括医疗保健投资银行的董事长；德意志银行证券—— 一家全球领先的投资银行，在那里他负责生命科学领域的执行和管理各种融资及并购交易。1992年8月至1995年1月，他曾担任德勤会计师事务所的会计师，一家独立注册会计师事务所；曾任会计师。他拥有美国加州大学伯克利分校文学士学位和斯坦福商学院经济学的工商管理硕士学位。
- Graham Cooper has served as a member of Board since October 2017. Mr. Cooper served as Chief Financial Officer and Chief Operating Officer of Assembly Biosciences, Inc. from March 2018 until April 2019. Mr. Cooper served as the Chief Financial Officer of Receptos, Inc. from February 2013 to August 2015 and as the Chief Financial Officer and Executive Vice President of Finance & Business Development at Geron Corporation from January 2012 to December 2012. Prior to that, Mr. Cooper served as Chief Financial Officer of Orexigen Therapeutics, Inc. and held several positions at Deutsche Bank Securities, including Director, Health Care Investment Banking. Mr. Cooper also worked as an accountant at Deloitte & Touche LLP, where he earned his CPA. Mr. Cooper has served as a member of the board of directors of Applied Molecular Therapeutics, Inc. since January 2020 Beam Therapeutics, Inc. since October 2019 and Unity Biotechnology, Inc. since August 2017. Mr. Cooper previously served as a member of the board of directors of Celladon Corporation. Mr. Cooper received a B.A. degree in economics from the University of California at Berkeley and an M.B.A. degree from the Stanford Graduate School of Business.
高管简历
中英对照 | 中文 | 英文- John Evans
John Evans自2018年8月起担任Verve Therapeutics, Inc.的董事会成员。Evans先生自2018年1月起担任生物技术公司Beam Therapeutics Inc.的首席执行官，并于2017年4月至2018年1月担任临时首席执行官。Evans先生与ARCH venture Partners担任风险合伙人，埃文斯先生曾于2009年9月至2017年3月受雇于生物制药公司Agios Pharmaceuticals，Inc.，最近担任公司发展和投资组合领导高级副总裁。在Agios，Evans先生还担任IDH投资组合执行官。在加入Agios之前，Evans先生曾就职于生物制药公司Infinity Pharmaceuticals，Inc.，麦肯锡公司的制药业务和生物制药公司AstraZeneca plc的全球生物制剂研发部门Medimune，LLC.伊万斯先生也在梁治疗公司董事会任职。伊万斯先生持有耶鲁大学的B.A，宾夕法尼亚大学的生物技术硕士学位和宾夕法尼亚大学沃顿商学院的医疗管理硕士学位。
John Evans,has significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Since September 2022, Mr. Evans has also served on the board of directors of Orbital Therapeutics, Inc., a biotechnology company focused on mRNA therapeutics. Mr. Evans previously served as a Venture Partner with ARCH Venture Partners from April 2017 to March 2021, and as a member of the board of directors of Verve Therapeutics from August 2018 to August 2022 and of Prime Medicines Inc. from September 2019 to September 2022. Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, from September 2009 until April 2017, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company's pharmaceuticals practice and MedImmune. Mr. Evans holds an MBA in Healthcare Management from Wharton, a M.S. in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.- John Evans自2018年8月起担任Verve Therapeutics, Inc.的董事会成员。Evans先生自2018年1月起担任生物技术公司Beam Therapeutics Inc.的首席执行官，并于2017年4月至2018年1月担任临时首席执行官。Evans先生与ARCH venture Partners担任风险合伙人，埃文斯先生曾于2009年9月至2017年3月受雇于生物制药公司Agios Pharmaceuticals，Inc.，最近担任公司发展和投资组合领导高级副总裁。在Agios，Evans先生还担任IDH投资组合执行官。在加入Agios之前，Evans先生曾就职于生物制药公司Infinity Pharmaceuticals，Inc.，麦肯锡公司的制药业务和生物制药公司AstraZeneca plc的全球生物制剂研发部门Medimune，LLC.伊万斯先生也在梁治疗公司董事会任职。伊万斯先生持有耶鲁大学的B.A，宾夕法尼亚大学的生物技术硕士学位和宾夕法尼亚大学沃顿商学院的医疗管理硕士学位。
- John Evans,has significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Since September 2022, Mr. Evans has also served on the board of directors of Orbital Therapeutics, Inc., a biotechnology company focused on mRNA therapeutics. Mr. Evans previously served as a Venture Partner with ARCH Venture Partners from April 2017 to March 2021, and as a member of the board of directors of Verve Therapeutics from August 2018 to August 2022 and of Prime Medicines Inc. from September 2019 to September 2022. Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, from September 2009 until April 2017, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company's pharmaceuticals practice and MedImmune. Mr. Evans holds an MBA in Healthcare Management from Wharton, a M.S. in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.
- Giuseppe Ciaramella
Giuseppe Ciaramella自2018年2月起担任我们的首席科学官，自2020年1月起担任我们的总裁兼首席科学官。Ciaramella博士拥有跨越不同治疗模式的25年药物发现经验，从小分子，到生物制剂，再到先进的医药产品，例如mRNA。在加入BEAM之前，Ciaramella博士于2014年至2018年2月担任Moderna Therapeutics传染病部门的首席科学官，在那里他帮助产生了一些首批LNP封装的mRNA疫苗，这些疫苗将用于人类，其中一些正在通过临床研究取得进展。从2011年到2014年，他曾担任AstraZeneca公司的执行董事，在那里他曾领导他们的小分子抗病毒战略。2010年至2011年间，他担任勃林格殷格翰大学的Vice President和合作研究主管，负责外部研究。任职Boehringer Ingelheim公司之前，他曾任职Pfizer公司（位于英国）14年，在那里他曾担任多种领导职务，包括生物疗法主管、抗病毒药物主管和HIT Discovery Group的负责人。Ciaramella博士是美国传染病学会（Infective Diseases Society of America）和美国基因治疗学会（American Society of Gene Therapy）的成员。Ciaramella博士拥有伦敦大学学院（University College London）生物化学博士学位。
Giuseppe Ciaramella,has 25 years of drug discovery experience across different therapeutic modalities, from small molecule, to biologics, to advanced medicinal products, such as mRNA. From March 2022 to September 2024, Dr. Ciaramella served as interim Chief Executive Officer and a member of the board of directors of Orbital Therapeutics, Inc. Prior to joining Beam, Dr. Ciaramella was the Chief Scientific Officer of the Infectious Diseases division of Moderna Therapeutics from 2014 until February 2018, where he was instrumental in generating some of the first LNP-encapsulated, mRNA vaccines to be dosed in humans, which technology formed the backbone of its authorized vaccine for the prevention of COVID-19. From 2011 until 2014, Dr. Ciaramella served as Executive Director at AstraZeneca, where he led their small molecule antiviral strategy. Between 2010 and 2011 he served as Vice President and Head of Collaborative Research at Boehringer Ingelheim, where he had responsibility for external research. Prior to Boehringer Ingelheim, he spent 14 years at Pfizer, Inc., in the United Kingdom where he held several leadership positions, including head of Biotherapeutics, head of Antivirals and head of the Hit Discovery Group. Dr. Ciaramella is a member of the Infectious Diseases Society of America and of the American Society of Gene Therapy. Dr. Ciaramella holds a Ph.D. in Biochemistry from University College London.- Giuseppe Ciaramella自2018年2月起担任我们的首席科学官，自2020年1月起担任我们的总裁兼首席科学官。Ciaramella博士拥有跨越不同治疗模式的25年药物发现经验，从小分子，到生物制剂，再到先进的医药产品，例如mRNA。在加入BEAM之前，Ciaramella博士于2014年至2018年2月担任Moderna Therapeutics传染病部门的首席科学官，在那里他帮助产生了一些首批LNP封装的mRNA疫苗，这些疫苗将用于人类，其中一些正在通过临床研究取得进展。从2011年到2014年，他曾担任AstraZeneca公司的执行董事，在那里他曾领导他们的小分子抗病毒战略。2010年至2011年间，他担任勃林格殷格翰大学的Vice President和合作研究主管，负责外部研究。任职Boehringer Ingelheim公司之前，他曾任职Pfizer公司（位于英国）14年，在那里他曾担任多种领导职务，包括生物疗法主管、抗病毒药物主管和HIT Discovery Group的负责人。Ciaramella博士是美国传染病学会（Infective Diseases Society of America）和美国基因治疗学会（American Society of Gene Therapy）的成员。Ciaramella博士拥有伦敦大学学院（University College London）生物化学博士学位。
- Giuseppe Ciaramella,has 25 years of drug discovery experience across different therapeutic modalities, from small molecule, to biologics, to advanced medicinal products, such as mRNA. From March 2022 to September 2024, Dr. Ciaramella served as interim Chief Executive Officer and a member of the board of directors of Orbital Therapeutics, Inc. Prior to joining Beam, Dr. Ciaramella was the Chief Scientific Officer of the Infectious Diseases division of Moderna Therapeutics from 2014 until February 2018, where he was instrumental in generating some of the first LNP-encapsulated, mRNA vaccines to be dosed in humans, which technology formed the backbone of its authorized vaccine for the prevention of COVID-19. From 2011 until 2014, Dr. Ciaramella served as Executive Director at AstraZeneca, where he led their small molecule antiviral strategy. Between 2010 and 2011 he served as Vice President and Head of Collaborative Research at Boehringer Ingelheim, where he had responsibility for external research. Prior to Boehringer Ingelheim, he spent 14 years at Pfizer, Inc., in the United Kingdom where he held several leadership positions, including head of Biotherapeutics, head of Antivirals and head of the Hit Discovery Group. Dr. Ciaramella is a member of the Infectious Diseases Society of America and of the American Society of Gene Therapy. Dr. Ciaramella holds a Ph.D. in Biochemistry from University College London.
- Sravan K. Emany
Sravan K. Emany，自2023年11月起担任公司董事，并自2024年12月起担任纳斯达克上市生物技术公司Beam Therapeutics Inc.的高级副总裁兼首席财务官。在加入Beam之前，Emany先生曾于2021年12月至2024年12月期间在医疗保健上市公司Ironwood Pharmaceuticals, Inc.担任高级副总裁兼首席财务官。在加入Ironwood之前，Emany先生于2020年3月至2021年12月期间担任Integra LifeSciences Holdings Corporation（一家全球医疗保健上市公司）的企业副总裁、商业卓越和首席战略官，并于2018年2月至2020年3月期间担任战略、财务和投资者关系副总裁。在加入Integra之前，Emany先生曾于2008年9月至2018年2月在美国银行和美国银行证券（前美银美林）担任多个并购投资银行职务，最终在并购集团担任董事总经理，领导了医疗保健领域的众多并购活动。Emany先生还担任过其他各种金融职务，包括在高盛萨克斯集团和摩根士丹利任职。Emany拥有约翰霍普金斯大学国际关系学士学位和约翰霍普金斯大学高级国际研究学院国际关系和国际经济学硕士学位。
Sravan K. Emany,has served as a director of the Company since November 2023 and has served as Senior Vice President and Chief Financial Officer of Beam Therapeutics Inc., a Nasdaq listed biotechnology company, since December 2024. Prior to joining Beam, Mr. Emany served as Senior Vice President and Chief Financial Officer of Ironwood Pharmaceuticals, Inc., a Nasdaq listed healthcare company, from December 2021 until December 2024. Prior to joining Ironwood, Mr. Emany served as Corporate Vice President, Commercial Excellence and Chief Strategy Officer of Integra LifeSciences Holdings Corporation, a publicly traded global healthcare company, from March 2020 until December 2021 and as Vice President of Strategy, Treasury and Investor Relations from February 2018 to March 2020. Prior to Integra, Mr. Emany served in various mergers and acquisitions investment banking roles at Bank of America and BofA Securities (formerly Bank of America Merrill Lynch) from September 2008 to February 2018, culminating in his service as managing director in the mergers and acquisitions group where he led numerous mergers and acquisitions in the healthcare sector. Mr. Emany also served in various other financial roles, including with Goldman Sachs Group and Morgan Stanley.Mr. Emany holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies.- Sravan K. Emany，自2023年11月起担任公司董事，并自2024年12月起担任纳斯达克上市生物技术公司Beam Therapeutics Inc.的高级副总裁兼首席财务官。在加入Beam之前，Emany先生曾于2021年12月至2024年12月期间在医疗保健上市公司Ironwood Pharmaceuticals, Inc.担任高级副总裁兼首席财务官。在加入Ironwood之前，Emany先生于2020年3月至2021年12月期间担任Integra LifeSciences Holdings Corporation（一家全球医疗保健上市公司）的企业副总裁、商业卓越和首席战略官，并于2018年2月至2020年3月期间担任战略、财务和投资者关系副总裁。在加入Integra之前，Emany先生曾于2008年9月至2018年2月在美国银行和美国银行证券（前美银美林）担任多个并购投资银行职务，最终在并购集团担任董事总经理，领导了医疗保健领域的众多并购活动。Emany先生还担任过其他各种金融职务，包括在高盛萨克斯集团和摩根士丹利任职。Emany拥有约翰霍普金斯大学国际关系学士学位和约翰霍普金斯大学高级国际研究学院国际关系和国际经济学硕士学位。
- Sravan K. Emany,has served as a director of the Company since November 2023 and has served as Senior Vice President and Chief Financial Officer of Beam Therapeutics Inc., a Nasdaq listed biotechnology company, since December 2024. Prior to joining Beam, Mr. Emany served as Senior Vice President and Chief Financial Officer of Ironwood Pharmaceuticals, Inc., a Nasdaq listed healthcare company, from December 2021 until December 2024. Prior to joining Ironwood, Mr. Emany served as Corporate Vice President, Commercial Excellence and Chief Strategy Officer of Integra LifeSciences Holdings Corporation, a publicly traded global healthcare company, from March 2020 until December 2021 and as Vice President of Strategy, Treasury and Investor Relations from February 2018 to March 2020. Prior to Integra, Mr. Emany served in various mergers and acquisitions investment banking roles at Bank of America and BofA Securities (formerly Bank of America Merrill Lynch) from September 2008 to February 2018, culminating in his service as managing director in the mergers and acquisitions group where he led numerous mergers and acquisitions in the healthcare sector. Mr. Emany also served in various other financial roles, including with Goldman Sachs Group and Morgan Stanley.Mr. Emany holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies.
- Christine Bellon
Christine Bellon，于2017年10月至2019年4月期间担任Forma Therapeutics的高级副总裁、总法律顾问和公司秘书。在加入Forma之前，Bellon博士于2016年7月至2017年10月担任Relay Therapeutics法律事务高级副总裁。在加入Relay之前，她曾在蓝图医药担任法律事务副总裁和公司秘书。在其职业生涯的早期，Bellon博士从事法律业务，曾在Hydra Biosciences和无限制药担任法律领导职务。贝隆博士拥有耶鲁大学化学学士学位；麻省理工学院有机化学博士学位，她曾在K. Barry Sharpless的实验室从事研究；哥伦比亚大学法学院法学博士学位。
Christine Bellon,served as Senior Vice President, General Counsel and Corporate Secretary for Forma Therapeutics from October 2017 until April 2019. Prior to Forma, Dr. Bellon was Senior Vice President of Legal Affairs for Relay Therapeutics from July 2016 until October 2017. Prior to Relay, she served as Vice President of Legal Affairs and Corporate Secretary at Blueprint Medicines. Earlier in her career, Dr. Bellon practiced law and served in legal leadership roles at Hydra Biosciences and Infinity Pharmaceuticals. Dr. Bellon holds a B.S. in chemistry from Yale University; a Ph.D. in organic chemistry from the Massachusetts Institute of Technology, where she did research in the laboratory of K. Barry Sharpless; and a J.D. from Columbia Law School.- Christine Bellon，于2017年10月至2019年4月期间担任Forma Therapeutics的高级副总裁、总法律顾问和公司秘书。在加入Forma之前，Bellon博士于2016年7月至2017年10月担任Relay Therapeutics法律事务高级副总裁。在加入Relay之前，她曾在蓝图医药担任法律事务副总裁和公司秘书。在其职业生涯的早期，Bellon博士从事法律业务，曾在Hydra Biosciences和无限制药担任法律领导职务。贝隆博士拥有耶鲁大学化学学士学位；麻省理工学院有机化学博士学位，她曾在K. Barry Sharpless的实验室从事研究；哥伦比亚大学法学院法学博士学位。
- Christine Bellon,served as Senior Vice President, General Counsel and Corporate Secretary for Forma Therapeutics from October 2017 until April 2019. Prior to Forma, Dr. Bellon was Senior Vice President of Legal Affairs for Relay Therapeutics from July 2016 until October 2017. Prior to Relay, she served as Vice President of Legal Affairs and Corporate Secretary at Blueprint Medicines. Earlier in her career, Dr. Bellon practiced law and served in legal leadership roles at Hydra Biosciences and Infinity Pharmaceuticals. Dr. Bellon holds a B.S. in chemistry from Yale University; a Ph.D. in organic chemistry from the Massachusetts Institute of Technology, where she did research in the laboratory of K. Barry Sharpless; and a J.D. from Columbia Law School.
- Amy Simon
Amy Simon，曾任职于阿尔尼拉姆制药，在基于RNA的药物的临床开发方面承担着越来越大的责任，最近担任临床开发副总裁。此前，西蒙博士曾担任塔夫茨大学医学院肺部和重症监护科哮喘中心的教授和主任，并担任塔夫茨生物医学科学研究生院的教授，她的实验室在那里进行了关于哮喘的基础科学研究。她的职业生涯始于临床实践，在塔夫茨医疗中心接受内科住院医师和肺部和重症监护医学研究员的培训。西蒙博士拥有哈佛大学历史和科学学士学位，塔夫茨大学医学院医学博士学位。
Amy Simon,worked at Alnylam Pharmaceuticals in roles with increasing responsibility for the clinical development of RNAi-based medicines, most recently as Vice President of Clinical Development. Previously, Dr. Simon served as a professor and a director of the Asthma Center in the Pulmonary and Critical Care Division at Tufts University School of Medicine and as a professor at Tufts Graduate School of Biomedical Science, where her laboratory conducted basic science research on asthma. She began her career in clinical practice, training as a resident in internal medicine and as a fellow in pulmonary and critical care medicine at Tufts Medical Center. Dr. Simon holds a B.A. in history and science from Harvard University, and an M.D. from Tufts University School of Medicine.- Amy Simon，曾任职于阿尔尼拉姆制药，在基于RNA的药物的临床开发方面承担着越来越大的责任，最近担任临床开发副总裁。此前，西蒙博士曾担任塔夫茨大学医学院肺部和重症监护科哮喘中心的教授和主任，并担任塔夫茨生物医学科学研究生院的教授，她的实验室在那里进行了关于哮喘的基础科学研究。她的职业生涯始于临床实践，在塔夫茨医疗中心接受内科住院医师和肺部和重症监护医学研究员的培训。西蒙博士拥有哈佛大学历史和科学学士学位，塔夫茨大学医学院医学博士学位。
- Amy Simon,worked at Alnylam Pharmaceuticals in roles with increasing responsibility for the clinical development of RNAi-based medicines, most recently as Vice President of Clinical Development. Previously, Dr. Simon served as a professor and a director of the Asthma Center in the Pulmonary and Critical Care Division at Tufts University School of Medicine and as a professor at Tufts Graduate School of Biomedical Science, where her laboratory conducted basic science research on asthma. She began her career in clinical practice, training as a resident in internal medicine and as a fellow in pulmonary and critical care medicine at Tufts Medical Center. Dr. Simon holds a B.A. in history and science from Harvard University, and an M.D. from Tufts University School of Medicine.